When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Abiraterone_acetate

   Abiraterone acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). [2] [6] [5] [4] This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists.

3. STAMPEDE (clinical trial) - Wikipedia

   en.wikipedia.org/wiki/STAMPEDE_(clinical_trial)

   James, Sydes & Clarke 2016 reported that "the addition of docetaxel to standard of care was associated with improved survival, with an HR of 0·78 and a difference in median survival of 10 months, as well as improvements in prostate-cancer-specific survival, failure-free survival, and skeletal-related events".

4. Niraparib/abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Niraparib/abiraterone_acetate

   Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib , a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate , a CYP17 inhibitor (hormone antagonist).

5. New treatment ‘increases chance of survival’ for prostate ...

   www.aol.com/treatment-increases-chance-survival...

   A total of 150 people took part in the trial. Patients with advanced prostate cancer have a greater chance of survival if treated with a targeted cancer drug in addition to chemotherapy, according ...

6. Prostate cancer shouldn’t be a death sentence. But for a ...

   www.aol.com/finance/prostate-cancer-shouldn-t...

   In fact, the five-year survival rate for prostate cancer detected early is virtually 100%, Siddiqui says. The outlook for late-diagnosed patients, however, is not nearly as rosy.

7. Novartis says radioligand therapy improves prostate cancer ...

   www.aol.com/news/novartis-radioligand-therapy...

   Novartis' experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday. The ...